SPRI | High-Risk IV Medications In Special Patient Populations (2011 EN)

Discussion in 'Medicine' started by Kanka, Aug 3, 2019.

  1. Kanka

    Kanka Well-Known Member Loyal User

    Messages:
    16,395
    Likes Received:
    485
    Trophy Points:
    83
    [​IMG]

    Author: Sandra Kane-Gill (Editor), Joseph Dasta (Editor)
    Full Title: High-Risk IV Medications In Special Patient Populations
    Publisher: Springer; 2011 edition (July 1, 2011)
    Year: 2011
    ISBN-13: 9780857296061 (978-0-85729-606-1), 9780857296054 (978-0-85729-605-4), 9781447158684 (978-1-4471-5868-4)
    ISBN-10: 085729606X, 0857296051, 1447158687
    Pages: 160
    Language: English
    Genre: Medicine: Anesthesiology
    File type: PDF (True, but nonnative Cover)
    Quality: 9/10
    Price: 149.79 €


    Critically ill patients are at risk for a higher frequency and severity of adverse drug events (ADEs), and special patient populations of the critically ill – requiring for instance individualized dosing due to non-average weight, hepatic or renal dysfunction, extracorporeal circulation devices, advanced age, pharmacogenetic alterations, hemodynamic instability, or therapeutic hypothermia – are particularly challenging. A contributing factor to this is the use of high-risk medications with many administered intravenously (IV). Hypervigilant monitoring of high-risk medications is still essential to prevent patient harm, especially in populations that have dosing challenges, hence, regulatory bodies internationally require active institutional surveillance of high-risk medications. These dosing challenges are a great safety concern, since there is considerable risk of unwanted adverse drug events from overdosing or therapeutic inefficacy from underdosing.

    High-Risk IV Medications in Special Patient Populations reviews high-risk IV medication dosage considerations for special patient populations and discusses the safety concerns of these medications to aid the clinician in cautious monitoring. The authors provide clinicians with tools to minimize adverse drug events with IV high-risk medications, while maximizing the beneficial clinical effects of these drugs, thus making this book essential reading for all involved with the care of critically ill patients.

    -------------
     
    Last edited by a moderator: Dec 3, 2019